References: Elborn et al, 1990
Elborn JS, Riley M, Stanford CF, Nicholls DP
The effects of flosequinan on submaximal exercise in patients with chronic
Br J Clin Pharmacol. 1990 May; 29(5): p.519-524.
Royal Victoria Hospital, Belfast, Northern Ireland.
1. Twenty patients with moderate to severe chronic cardiac failure were entered
into a double-blind parallel group study comparing flosequinan 100 mg daily with
matching placebo. 2. After at least three prior exercise tests, cardiopulmonary
parameters were assessed at rest and during submaximal exercise before and after
2 and 8 weeks of active drug or placebo. 3. Resting minute ventilation and
respiratory rate were reduced by flosequinan compared with placebo, but oxygen
uptake was unchanged. 4. Comparison of minute ventilation, carbon dioxide
production and venous lactate levels at the end of the exercise stage
approximating to 50% of peak oxygen uptake demonstrated significant reductions
in the flosequinan group compared with placebo at week 2 and week 8 (P less than
0.05). 5. Flosequinan increased the oxygen uptake at anaerobic threshold from
13.2 +/- 2.8 ml min-1 kg-1 to 15.9 +/- 3.4 ml min-1 kg-1 at week 2 and 15.8 +/-
3.7 ml min-1 kg-1 at week 8. These increases were significant when compared with
placebo (P less than 0.05). 6. We conclude that flosequinan improves submaximal
exercise performance in patients with chronic cardiac failure, probably by
enhancing skeletal muscle blood flow.